API Holdings Ltd (PharmEasy)

Digital pharmacy and pharma distribution group working through a heavy deleveraging cycle.

UnlistedMedium liquidityHealthtech & Pharmacy DistributionISIN INE05HQ01026New ageDeleveragingHigh risk

Indicative price

₹7.83

+0.00 (+0.00%) today

BuySell

Market cap

₹6,201 Cr

792.00 Cr shares

P/E ratio

Loss making

Sector average 40

Book value

₹2.94

P/B 2.66

1-year return

-7.56%

52w ₹7 – ₹14

52-week low ₹752-week high ₹14

Currently 6% of the way through its 52-week range.

Indicative price history

1Y change

-7.56% ₹8₹8

14.112.410.68.97.2Sept 25Nov 25Feb 26Apr 26Jun 26Sept 26

52-week band in this window: ₹7.83₹13.43. Weekly indicative marks, not exchange-traded prices.

Key highlights

  • Largest online pharmacy platform in India by orders, plus a top-three pharma distributor.
  • Debt cut by more than half in two years through asset sales and a rights issue.
  • Operating cash flow turned positive in FY26.

About PharmEasy

API Holdings is the parent of a digital pharmacy platform, a pharma wholesale distribution business and a diagnostics chain.

The consumer platform sells prescription and over-the-counter medicines with home delivery, while the distribution arm supplies retail chemists.

After an aggressive acquisition phase the group has been selling non-core assets and using proceeds to repay debt.

Where the revenue comes from

  • Pharma distribution58%

    Wholesale supply to retail chemists

  • Consumer platform27%

    Online pharmacy orders

  • Diagnostics11%

    Pathology labs and collection centres

  • Other services4%

    Teleconsultation and software

Products & services

PharmEasy

Consumer e-pharmacy and teleconsultation app.

Retailio

B2B marketplace for retail chemists.

Thyrocare (stake)

Diagnostics chain, listed subsidiary.

Docon

Clinic management software.

What works

  • Scale in pharma distribution gives purchasing leverage with manufacturers.
  • Repeat purchase behaviour in chronic medication supports predictable order flow.
  • Deleveraging has cut interest cost meaningfully from the peak.

What to watch

  • The group has a history of large losses and goodwill write-downs from past acquisitions.
  • Regulatory uncertainty around online sale of prescription medicines persists.
  • A down round in the past has left many earlier investors holding losses.

Compare with peers

CompanyPriceMarket capP/EP/BRev CAGR
PharmEasyThis page₹7.83₹6,201 Cr2.66-0.39%
OYO₹23.40₹21,185 Cr21.276.94+31.78%
ESDS₹405.00₹4,617 Cr51.868.40+24.34%

Latest reported year: FY26 ending 31 Mar 2026.